0001144204-18-012823.txt : 20180305 0001144204-18-012823.hdr.sgml : 20180305 20180305170047 ACCESSION NUMBER: 0001144204-18-012823 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180301 FILED AS OF DATE: 20180305 DATE AS OF CHANGE: 20180305 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PRZYBYL ARTHUR CENTRAL INDEX KEY: 0001268135 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31812 FILM NUMBER: 18667013 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ANI PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001023024 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 582301143 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 210 MAIN STREET WEST CITY: BAUDETTE STATE: MN ZIP: 56623 BUSINESS PHONE: 2186343500 MAIL ADDRESS: STREET 1: 210 MAIN STREET WEST CITY: BAUDETTE STATE: MN ZIP: 56623 FORMER COMPANY: FORMER CONFORMED NAME: BIOSANTE PHARMACEUTICALS INC DATE OF NAME CHANGE: 19991228 FORMER COMPANY: FORMER CONFORMED NAME: BEN ABRAHAM TECHNOLOGIES INC DATE OF NAME CHANGE: 19991027 4 1 tv487707_form4.xml FORM 4 X0306 4 2018-03-01 0 0001023024 ANI PHARMACEUTICALS INC ANIP 0001268135 PRZYBYL ARTHUR C/O ANI PHARMACEUTICALS, INC. 210 MAIN STREET WEST BAUDETTE MN 56623 1 1 0 0 President and CEO Common Stock 2018-03-01 4 M 0 9375 40.59 A 219358 D Common Stock 2018-03-01 4 M 0 6375 33.00 A 225733 D Common Stock 2018-03-01 4 M 0 8236 6.36 A 233969 D Common Stock 2018-03-01 4 S 0 11326 60.59 D 222643 D Common Stock 2018-03-01 4 S 0 8400 61.62 D 214243 D Common Stock 2018-03-01 4 S 0 4260 62.17 D 209983 D Stock Option 40.59 2018-03-01 4 M 0 9375 0 D 2026-04-06 Common Stock 9375 28125 D Stock Option 33.00 2018-03-01 4 M 0 6375 0 D 2024-03-31 Common Stock 6375 6375 D Stock Option 6.36 2018-03-01 4 M 0 8236 0 D 2023-07-11 Common Stock 8236 15723 D This transaction was executed in multiple trades at prices ranging from $60.00 to $60.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $61.00 to $61.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $62.00 to $62.525. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The options vest and become exercisable in equal annual amounts over a four-year period beginning on the first anniversary of the grant date. The grant date was April 7, 2016. The options vested and become exercisable in equal annual amounts over a four-year period beginning on the first anniversary of the grant date. The grant date was April 1, 2014. The options vested and become exercisable in equal annual amounts over a four-year period beginning on the first anniversary of the grant date. The grant date was July 12, 2013. /s/ Arthur Przybyl 2018-03-05